Polyganics Appoints Two New Supervisory Board Members

Informations

• Publié par: polyganics
• Nombre de lectures: 15
• Langue: English

Extrait

Polyganics Appoints Two New Supervisory

Board Members

PR Newswire

GRONINGEN, The Netherlands, July 4, 2012

GRONINGEN,

The Netherlands

,

July 4, 2012

/PRNewswire/ --

Dr. Cees de Jong (former COO Crucell) appointed

Chairman of the Board.

Ms. Annemieke Wouterse (N.O.M.) appointed member

of the board.

Polyganics today announced the following appointments:

Dr. Cees de Jong

(1961) joins Polyganics Supervisory Board to act as

Chairman.

Mr. De Jong was the Chief Operating Officer and a member of the Management

Board of Dutch Biotechnology company Crucell till its successful merger with

Johnson & Johnson in 2011. Under De Jong's leadership Crucell accelerated its

revenue growth and improved profitability significantly.

Before joining Crucell, Mr. De Jong was Group Vice President at Quest

International, an ICI company. He was a member of Quest International's

Management Board and responsible for turning around the Flavours Division,

leading to € 1,8 billion acquisition of Quest by market leader Givaudan. Prior to

Quest, he worked as Managing Director of DSM Anti-infectives. In 1989, Mr. de

Jong started his career at Gist Brocades where he held several managerial roles

of increasing responsibility.

Mr. de Jong holds a Medical Degree as well as an MBA from the Erasmus

University Rotterdam.

Ms. Annemieke Wouterse

joins Polyganics Supervisory board, representing

NOM the regional development agency for the

Northern Netherlands

. Wouterse

is an experienced investment manager, managing over 20 participations

including acquisition and valuation responsibilities.

Before joining NOM in 1999 she held various senior consultancy and controller

roles in companies like Bakkenist, AVEBE and AkzoNobel. Ms Wouterse holds a

bachelor in economics from Erasmus University Rotterdam as well as a

controller degree from Free University Amsterdam. She recently completed the

supervisory board program at the Nyenrode Business University.

"I am very pleased to welcome in our Board such experienced and highly

qualified senior executives", says

Chief Executive Officer Maarten

Nibbelke

. "Cees will strengthen the Board with his extensive international

experience and his proven achievements in operational excellence. Annemieke

will strengthen the board with her extensive financial background and long

lasting relationship between our company and the NOM as one of the initial

investors in Polyganics. We are confident that both will make an important

contribution to achieve our ambitious development and growth strategy in

bioresorbable medical devices.

Mr. de Jong and Ms. Wouterse will be replacing Mr. van Mulukom and Mr.

Jensma, both retiring effective today after a long and well appreciated period of

contribution to Polyganics"

About Polyganics

Polyganics is a privately held biomedical company founded in 1998 as a spin off

from the Groningen University in

the Netherlands

focused on bioresorbable

medical devices.

Polyganics develops, manufactures and markets worldwide a range of

innovative biomedical products based on Bioresorbable polymers used in

various surgical applications with global brands including NASOPORE

®

,

OTOPORE

®

, NEUROLAC

®

, VIVOSORB

®

and C-SEAL

®

.

For additional inquiries please contact our office in

the Netherlands

, Ms. Marla

Kost; email [e-mail] phone [phone].